Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422778 | 0.93 | CYP19A1 (0.45) | AHRPRMT1ITKCYP2A6NR4A2 | |
| SCHEMBL17422776 | 0.93 | CYP19A1 (0.45) | AHRPRMT1ITKCYP2A6NR4A2 | |
| SCHEMBL17422806 | 0.91 | CYP2A6 (0.53) | ITKCYP2A6BCHEACHEMAPT | |
| SCHEMBL17422756 | 0.91 | PRMT1 (0.48) | AHRPRMT1NOS1METAP2DYRK1A | |
| SCHEMBL17422807 | 0.91 | CYP2A6 (0.53) | ITKCYP2A6BCHEACHEMAPT | |
| SCHEMBL17422755 | 0.91 | PRMT1 (0.48) | AHRPRMT1NOS1METAP2DYRK1A | |
| SCHEMBL17433481 | 0.88 | TUBB4A (0.46) | PRMT1CYP2A6BCHEACHEMAPT | |
| SCHEMBL19179899 | 0.87 | NOS1 (0.41) | AHRPRMT1NOS1METAP2DYRK1A | |
| SCHEMBL17433391 | 0.87 | NOS1 (0.41) | AHRPRMT1NOS1METAP2DYRK1A | |
| SCHEMBL19180054 | 0.85 | PRMT1 (0.44) | PRMT1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | AHR 4643/4885PRMT1 2208/4885NOS1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.